Tokyo, Japan – September 3, 2025 – Eisai Co., Ltd., a leading global pharmaceutical company, is set to unveil new clinical data on its sleep disorder treatments at the upcoming World Sleep 2025 congress. The company announced today that it will present a comprehensive collection of 11 presentations, highlighting advancements in the understanding and treatment of sleep disorders.

A significant portion of Eisai's presentations will focus on lemborexant, a currently available medication designed to improve sleep onset and maintenance. The data presented on lemborexant is expected to provide further insights into its efficacy, safety profile, and potential benefits for various patient populations struggling with insomnia.

Adding to the excitement, Eisai will also be showcasing its innovative research on E2086, a novel selective orexin 2 receptor agonist (OX2R). Orexin is a naturally occurring neuropeptide in the brain that plays a crucial role in regulating wakefulness. By selectively targeting the orexin 2 receptor, E2086 aims to promote wakefulness during the day, potentially offering a new approach to treating sleep disorders characterized by excessive daytime sleepiness.

The presentations on E2086 are highly anticipated, as they represent a promising avenue for developing new therapies that address the underlying causes of certain sleep disorders. The data shared at World Sleep 2025 will likely cover preclinical and potentially early-stage clinical findings, shedding light on the drug's mechanism of action, safety, and potential efficacy in improving daytime wakefulness and overall quality of life for patients.

"We are excited to share our latest research and clinical findings at World Sleep 2025," stated a representative from Eisai. "Our commitment to advancing the science of sleep is unwavering, and we believe that these presentations will contribute significantly to the ongoing effort to develop effective and innovative treatments for a wide range of sleep disorders."

World Sleep 2025 is a premier international congress that brings together leading sleep researchers, clinicians, and industry professionals from around the globe. Eisai's participation underscores its dedication to addressing the unmet needs of individuals affected by sleep disorders and its commitment to driving innovation in this critical area of healthcare. The company's presentations are expected to generate considerable interest and discussion among attendees, potentially shaping the future of sleep medicine.